About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Medicine still has many challenges to solve specially on complex diseases were a large number of both, genetic and environmental factors are involved. Among them, neurodegenerative and autoimmune disorders affecting the central nervous system have attracted attention because CNS is difficult to access and to manipulate with classical pharmacological treatments and, in addition, there are no effective curative treatments for these diseases. To address these problems, we have focused our research interests in gene therapy strategies for autoimmune diseases and neurodegenerative disorders specially those associated to aging.
IP: Miguel Chillon Rodriguez Collaborators: - Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 0.01 Reference: RED2022-134221-T Duration: 01/06/2023 - 31/05/2025
IP: Miguel Chillon Rodriguez Collaborators: Susana Miravet Delgado, Laia Rubio Ortega, Marina Tarrés Mercader, ESTUDIO Y DESARROLLO DE LA PRIMERA PLATAFORMA TECNOLÓGICA DE ENSAYOS PARA VIRUS ADENOASOCIADOS EN TERÁPIA GÉNICA Funding agency: Instituto de Salud Carlos III Funding: 296571 Reference: PMPTA22/00048 Duration: 01/01/2023 - 30/06/2025
IP: Miguel Chillon Rodriguez Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 169097.5 Reference: AC20/00051 Duration: 01/01/2021 - 31/10/2024
The donation will enable further characterisation of patients with this rare disease, the identification of new biomarkers and the exploration of innovative therapies.
The Gen Rebelde Foundation has made the first donation of the year to the gene therapy research project for GNB1 encephalopathy.
The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB) with the participation of VHIR.
Check the current rates for the services offered by the Gene Therapy at Nervous System research group.
Group Current Rates
PDF 0.48 MB
Group Rates (2021)
PDF 3.06 MB
